Albemarle — Apr 30, 2025 release

Segment FY 2025E Specialties net sales $1.3 - $1.5 billion Specialties adjusted EBITDA $210 - $280 million Ketjen net sales $1.0 - $1.1 billion Ketjen adjusted EBITDA $120 - $150 million Other Corporate Outlook Considerations Albemarle expects its 2025 capital expenditures to be in the range of $700 million to $800 million, down more than 50% from $1.7 billion in 2024. This level of spending reflects a prioritization on sustaining existing assets and resources, with the remainder allocated to select growth projects and high-return, quick payback improvements. Other Corporate FY 2025E Capital expenditures $700 - $800 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40%) - 25% Corporate costs (b) $70 - $100 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a)    Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b)    FY 2025E outlook includes FX impact year to date Cash Flow and Capital Deployment Cash from operations of $545 million increased $447 million compared to the prior-year period. A customer prepayment received in January and improved working capital more than offset lower adjusted EBITDA and reduced dividends received from equity investments. Capital expenditures of $183 million decreased by $397 million versus the prior-year period, reflecting the impact of decisions that stopped or slowed spending and the completion of capacity expan